The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Slides:



Advertisements
Similar presentations
Therapy of Type 2 Diabetes Mellitus: UPDATE
Advertisements

Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Practical Implementation as a Discussion with the Patient, Part 2 Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Toujeo® and it’s Place in Therapy
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Medical Professionals
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM (Part 1) Stan Schwartz MD, FACP, FACE.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Therapy of Type 2 Diabetes Mellitus: UPDATE
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM (Part 2) Stan Schwartz MD, FACP, FACE.
SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.
Adding Prandial Insulin to Basal Insulin: Key Challenges
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Lifestyle Modifications
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
Management of Diabetes in the Older Person
NATURAL HISTORY OF BETA CELL FAILURE IN T2DM
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Management of Diabetes in the Older Person
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
↑- likely due to hypoglycemia and weight gain
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Add-On Therapy to Insulin in T1DM Management
Obesity Management.
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.
Presentation transcript:

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program Cardiometabolic Diabetes Center and Affiliate, Main Line Health System Emeritus, Clinical Associate Professor University of Pennsylvania Part 9 * *Part 9 of 9

Weight Reduction Issues- Non -Insulin 0. In Metabolic Syndrome-consider Incretins/ SGLT-2 inh non-insulin agents before consider insulin a. Not SU/GLINIDE b. AACE first Tier/ Second Tier Principle c. Beta cell- incretin/SGLT-2 Inh/ Pio d. Resistance- Pio/ metformin e. Other- bromocriptine-QR, colsevalam F. EARLY TRIPLE THERAPY 2. Incretins Before Pioglitazone- then don’t gain weight from pioglitazone 3. Ranolazine, SGLT-2 inh to minimize/prevent edema from pioglitazone 4.. GLP-1 RA’s and SGLT-2s have added wt. loss benefit 5. GLP-1 RA’s preferred over DPP-4 in ‘right patient’ 6. GLP-1 RA’s always before start Insulin, even a short trial-

1. UNLESS ‘SICK’, AVOID INSULIN IF NOT FOLLOWING NCS DIET 2. KEEP NON-INSULIN TREATMENTS AS START BASAL- KEEP ON INCRETIN/SGLT-2 INHIBITOR (OTHERS) WHEN ADD INSULIN IF DO SO ONLY ~10% NEED BOLUS. IF ON INSULIN- AS START NCS DIET, DECREASE 25% IF WAS HAVING HYPOGLYCEMIA DECREASE 25% ADD INCRETIN, GLP-1 PREFERRED – DEC. INSULIN AS DO SO ADD SGLT-2 INHIBITOR- DECREASE INSULINS 25% ADD PIOGLITAZONE, METFORMIN, IF POSSIBLE MAY BE ABLE TO STOP INSULIN, LOSE WEIGHT THUS NEW PATIENTS WHO COME TO ME ON INSULIN <40 UNITS/D, NOT ON DIET, HYPOGLYEMIA, EPISODES, I STOP INSULIN START DIET GLP-1 RA AND SGLT-2 INHIBITOR Weight Reduction Issues- Insulin

Summary Epidemiology and Economics of obesity/diabetes-costly Perspectives on Obesity- culture Consequences of Obesity, Prediabetes, Obesity Obesity/ Diabetes Risk Factors, Obesity/ Diabetes Onset can be Prevented or Delayed – Early Risk Identification and Intervention. Medical Benefits to Weight Loss Treatment-CDC’s diabetes prevention program and other Evidence-Based Interventions- We can do Better, We must do better